The KRAS p.Gly12Cys mutation became a new target for personalized therapy with the sotorasib and adagrasib.23,25,26,31 Our study analyzed the frequency of p.Gly12Cys mutation in the Brazilian NSCLC population. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.